Global Information
회사소개 | 문의

루게릭병 : 파이프라인 리뷰

Amyotrophic Lateral Sclerosis - Pipeline Review, H2 2018

리서치사 Global Markets Direct
발행일 2018년 10월 상품 코드 232799
페이지 정보 영문 551 Pages
가격
US $ 2,000 ₩ 2,278,800 PDF by E-mail (Single user license) help
1명만 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 4,000 ₩ 4,557,600 PDF by E-mail (Site license) help
동일 사업장 내 모든 분들이 공유하여 사용할 수 있습니다. 이용 인원수에 제한은 없습니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 2부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 6,000 ₩ 6,836,400 PDF by E-mail (Global license) help
동일 기업의 모든 분들이 이용할 수 있는 라이선스입니다. 이용 인원수에 제한은 없으며, 해외 사업장 및 100% 자회사는 동일 기업으로 간주됩니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 10부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.


루게릭병 : 파이프라인 리뷰 Amyotrophic Lateral Sclerosis - Pipeline Review, H2 2018
발행일 : 2018년 10월 페이지 정보 : 영문 551 Pages

이 페이지에 게재되어 있는 내용은 최신판과 약간 차이가 있을 수 있으므로 영문목차를 함께 참조하여 주시기 바랍니다. 기타 자세한 사항은 문의 바랍니다.

루게릭병(ALS)은 운동 뉴런 시스템의 가장 일반적인 변성 질환입니다. 이 장애는 원인이 되는 병태생리학으로부터 명명되었으며, 근섬유 위축에 관한 근위축증을 수반하고 대응하는 전각세포가 퇴화함에 따라 신경이 마비되어 갑니다. 이 영역의 상위 운동 뉴런(UMN) 축색이 변질되고 신경교증을 대신하므로 측색경화증은 척수의 측주에서 보이는 변화와 관계가 있습니다. 증후로 호흡 곤란, 연하장애, 목의 근력 저하로 앞으로 처지는 머리, 근경련, 느리고 이상한 말투(불분명한 발음 등) 등의 회화 장애, 변성, 쉰 목소리, 체중 감소 등을 볼 수 있습니다.

루게릭병(Amyotrophic Lateral Sclerosis) 치료제 개발 파이프라인 현황과 최신 업데이트에 의한 각 개발 단계 비교 분석, 기업과 연구기관이 개발중인 치료제, 치료제 평가, 후기 단계 및 중지된 프로젝트 관련 정보, 최신 뉴스와 발표 등의 정보를 전해드립니다.

서론

루게릭병 개요

치료제 개발

치료제 평가

치료제 개발 참여 기업

약제 개요

최근 파이프라인 동향

휴지 상태의 프로젝트

개발이 중지된 제품

제품 개발 마일스톤

부록

도표

LSH 17.07.24

List of Tables

  • Number of Products under Development for Amyotrophic Lateral Sclerosis, H2 2018
  • Number of Products under Development by Companies, H2 2018
  • Number of Products under Development by Universities/Institutes, H2 2018
  • Products under Development by Companies, H2 2018
  • Products under Development by Universities/Institutes, H2 2018
  • Number of Products by Stage and Target, H2 2018
  • Number of Products by Stage and Mechanism of Action, H2 2018
  • Number of Products by Stage and Route of Administration, H2 2018
  • Number of Products by Stage and Molecule Type, H2 2018
  • Amyotrophic Lateral Sclerosis - Pipeline by AB Science SA, H2 2018
  • Amyotrophic Lateral Sclerosis - Pipeline by Acceleron Pharma Inc, H2 2018
  • Amyotrophic Lateral Sclerosis - Pipeline by Affichem SA, H2 2018
  • Amyotrophic Lateral Sclerosis - Pipeline by Alexion Pharmaceuticals Inc, H2 2018
  • Amyotrophic Lateral Sclerosis - Pipeline by Anavex Life Sciences Corp, H2 2018
  • Amyotrophic Lateral Sclerosis - Pipeline by Apogenix AG, H2 2018
  • Amyotrophic Lateral Sclerosis - Pipeline by Apotex Inc, H2 2018
  • Amyotrophic Lateral Sclerosis - Pipeline by Aquestive Therapeutics Inc, H2 2018
  • Amyotrophic Lateral Sclerosis - Pipeline by ArmaGen Inc, H2 2018
  • Amyotrophic Lateral Sclerosis - Pipeline by Avanir Pharmaceuticals Inc, H2 2018
  • Amyotrophic Lateral Sclerosis - Pipeline by AveXis Inc, H2 2018
  • Amyotrophic Lateral Sclerosis - Pipeline by Axovant Sciences Ltd, H2 2018
  • Amyotrophic Lateral Sclerosis - Pipeline by Bactevo Ltd, H2 2018
  • Amyotrophic Lateral Sclerosis - Pipeline by Bausch Health Companies Inc, H2 2018
  • Amyotrophic Lateral Sclerosis - Pipeline by BioElectron Technology Corp, H2 2018
  • Amyotrophic Lateral Sclerosis - Pipeline by Biogen Inc, H2 2018
  • Amyotrophic Lateral Sclerosis - Pipeline by Biohaven Pharmaceutical Holding Company Ltd, H2 2018
  • Amyotrophic Lateral Sclerosis - Pipeline by BioHealthonomics Inc, H2 2018
  • Amyotrophic Lateral Sclerosis - Pipeline by BrainStorm Cell Therapeutics Inc, H2 2018
  • Amyotrophic Lateral Sclerosis - Pipeline by Calico LLC, H2 2018
  • Amyotrophic Lateral Sclerosis - Pipeline by CerSci Therapeutics Inc, H2 2018
  • Amyotrophic Lateral Sclerosis - Pipeline by Chronos Therapeutics Ltd, H2 2018
  • Amyotrophic Lateral Sclerosis - Pipeline by Chugai Pharmaceutical Co Ltd, H2 2018
  • Amyotrophic Lateral Sclerosis - Pipeline by Corcept Therapeutics Inc, H2 2018
  • Amyotrophic Lateral Sclerosis - Pipeline by Corestem Inc, H2 2018
  • Amyotrophic Lateral Sclerosis - Pipeline by CSPC NBP Pharmaceutical Co Ltd, H2 2018
  • Amyotrophic Lateral Sclerosis - Pipeline by Cytokinetics Inc, H2 2018
  • Amyotrophic Lateral Sclerosis - Pipeline by Denali Therapeutics Inc, H2 2018
  • Amyotrophic Lateral Sclerosis - Pipeline by Disarm Therapeutics Inc, H2 2018
  • Amyotrophic Lateral Sclerosis - Pipeline by Eisai Co Ltd, H2 2018
  • Amyotrophic Lateral Sclerosis - Pipeline by Emerald Health Sciences Inc, H2 2018
  • Amyotrophic Lateral Sclerosis - Pipeline by FPRT Bio Inc, H2 2018
  • Amyotrophic Lateral Sclerosis - Pipeline by Gemac SA, H2 2018
  • Amyotrophic Lateral Sclerosis - Pipeline by Genentech Inc, H2 2018
  • Amyotrophic Lateral Sclerosis - Pipeline by Genervon Biopharmaceuticals LLC, H2 2018
  • Amyotrophic Lateral Sclerosis - Pipeline by GeNeuro SA, H2 2018
  • Amyotrophic Lateral Sclerosis - Pipeline by Gilead Sciences Inc, H2 2018
  • Amyotrophic Lateral Sclerosis - Pipeline by Glialogix Inc, H2 2018
  • Amyotrophic Lateral Sclerosis - Pipeline by Grifols SA, H2 2018

List of Figures

  • Number of Products under Development for Amyotrophic Lateral Sclerosis, H2 2018
  • Number of Products under Development by Companies, H2 2018
  • Number of Products under Development by Universities/Institutes, H2 2018
  • Number of Products by Top 10 Targets, H2 2018
  • Number of Products by Stage and Top 10 Targets, H2 2018
  • Number of Products by Top 10 Mechanism of Actions, H2 2018
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2018
  • Number of Products by Routes of Administration, H2 2018
  • Number of Products by Stage and Routes of Administration, H2 2018
  • Number of Products by Top 10 Molecule Types, H2 2018
  • Number of Products by Stage and Top 10 Molecule Types, H2 2018

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Amyotrophic Lateral Sclerosis - Pipeline Review, H2 2018, provides an overview of the Amyotrophic Lateral Sclerosis (Central Nervous System) pipeline landscape.

Amyotrophic lateral sclerosis (ALS) is the most common degenerative disease of the motor neuron system. The disorder is named for its underlying pathophysiology, with amyotrophy referring to the atrophy of muscle fibers, which are denervated as their corresponding anterior horn cells degenerate. Lateral sclerosis refers to the changes seen in the lateral columns of the spinal cord as upper motor neuron (UMN) axons in these areas degenerate and are replaced by fibrous astrocytes (gliosis). Symptoms include difficulty breathing, difficulty swallowing, head drop due to weakness of the neck muscles, muscle cramps, speech problems, such as a slow or abnormal speech pattern (slurring of words), voice changes, hoarseness, weight loss.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Amyotrophic Lateral Sclerosis - Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Amyotrophic Lateral Sclerosis (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Amyotrophic Lateral Sclerosis (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Amyotrophic Lateral Sclerosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 2, 1, 6, 25, 16, 2, 89, 26 and 3 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 32 and 10 molecules, respectively.

Amyotrophic Lateral Sclerosis (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Amyotrophic Lateral Sclerosis (Central Nervous System).
  • The pipeline guide reviews pipeline therapeutics for Amyotrophic Lateral Sclerosis (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Amyotrophic Lateral Sclerosis (Central Nervous System) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Amyotrophic Lateral Sclerosis (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Amyotrophic Lateral Sclerosis (Central Nervous System)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Amyotrophic Lateral Sclerosis (Central Nervous System).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Amyotrophic Lateral Sclerosis (Central Nervous System) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
  • Introduction
  • Amyotrophic Lateral Sclerosis - Overview
  • Amyotrophic Lateral Sclerosis - Therapeutics Development
  • Amyotrophic Lateral Sclerosis - Therapeutics Assessment
  • Amyotrophic Lateral Sclerosis - Companies Involved in Therapeutics Development
  • Amyotrophic Lateral Sclerosis - Drug Profiles
  • Amyotrophic Lateral Sclerosis - Dormant Projects
  • Amyotrophic Lateral Sclerosis - Discontinued Products
  • Amyotrophic Lateral Sclerosis - Product Development Milestones
  • Appendix
Back to Top
전화 문의
이용안내
 
BCC Research